Roche Holding AG
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $315
- Today's High:
- $315
- Open Price:
- $315
- 52W Low:
- $283.7001
- 52W High:
- $416.9665
- Prev. Close:
- $315
- Volume:
- 0
Company Statistics
- Market Cap.:
- $230.26 billion
- Book Value:
- 33.2
- Revenue TTM:
- $63.14 billion
- Operating Margin TTM:
- 31.09%
- Gross Profit TTM:
- $47.83 billion
- Profit Margin:
- 17.47%
- Return on Assets TTM:
- 14.34%
- Return on Equity TTM:
- 40.25%
Company Profile
Roche Holding AG had its IPO on under the ticker symbol RHHBF.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Roche Holding AG has a staff strength of 103,613 employees.
Stock update
Shares of Roche Holding AG opened at $315 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $315 - $315, and closed at $315.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Roche Holding AG have increased by +1.61%.
Roche Holding AG's Key Ratios
Roche Holding AG has a market cap of $230.26 billion, indicating a price to book ratio of 11.6129 and a price to sales ratio of 4.1146.
In the last 12-months Roche Holding AG’s revenue was $63.14 billion with a gross profit of $47.83 billion and an EBITDA of $23.00 billion. The EBITDA ratio measures Roche Holding AG's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Roche Holding AG’s operating margin was 31.09% while its return on assets stood at 14.34% with a return of equity of 40.25%.
In Q2, Roche Holding AG’s quarterly earnings growth was a negative -15.8% while revenue growth was a negative 9.7%.
Roche Holding AG’s PE and PEG Ratio
- Forward PE
- 17.1233
- Trailing PE
- 20.5346
- PEG
- 4.1761
Its diluted EPS in the last 12-months stands at $15.34 per share while it has a forward price to earnings multiple of 17.1233 and a PEG multiple of 4.1761. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Roche Holding AG’s profitability.
Roche Holding AG stock is trading at a EV to sales ratio of 4.4719 and a EV to EBITDA ratio of 12.474. Its price to sales ratio in the trailing 12-months stood at 4.1146.
Roche Holding AG stock pays annual dividends of $9.5 per share, indicating a yield of 3.25% and a payout ratio of 69.34%.
Balance sheet and cash flow metrics
- Total Assets
- $84.37 billion
- Total Liabilities
- $26.21 billion
- Operating Cash Flow
- $736.50 million
- Capital Expenditure
- $842.50 million
- Dividend Payout Ratio
- 69.34%
Roche Holding AG ended 2024 with $84.37 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $84.37 billion while shareholder equity stood at $26.52 billion.
Roche Holding AG ended 2024 with $0 in deferred long-term liabilities, $26.21 billion in other current liabilities, in common stock, $38.33 billion in retained earnings and $10.56 billion in goodwill. Its cash balance stood at $3.72 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $20.35 billion.
Roche Holding AG’s total current assets stands at $30.98 billion while long-term investments were $0 and short-term investments were $3.79 billion. Its net receivables were $11.09 billion compared to accounts payable of $4.06 billion and inventory worth $8.50 billion.
In 2024, Roche Holding AG's operating cash flow was $736.50 million while its capital expenditure stood at $842.50 million.
Comparatively, Roche Holding AG paid $0.69 in dividends in 2024.
Other key metrics
- Current Trading Price
- $315
- 52-Week High
- $416.9665
- 52-Week Low
- $283.7001
- Analyst Target Price
- $
Roche Holding AG stock is currently trading at $315 per share. It touched a 52-week high of $416.9665 and a 52-week low of $416.9665. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $324.14 and 200-day moving average was $336.06 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7278.5% of the company’s stock are held by insiders while 864.3% are held by institutions.
Frequently Asked Questions About Roche Holding AG
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.